Vir Biotechnology president and CEO George Scangos explains why many companies struggle to build a sustainable business model around fighting infectious diseases, particularly when it comes to developing antibiotics. However, he adds, certain therapies for viral diseases are currently more financially viable. Dr. Scangos explores why Vir decided to go “all-in” on infectious diseases, how they built a company around that mission, and how the arrival of COVID-19 impacted the young company’s trajectory.
Related
Stephanie Lampkin,
Blendoor
Data-Powered Diversity [Entire Talk]
Data can be a powerful ally in building diverse organizations.
Stephanie Lampkin,
Blendoor
Data-Powered Diversity [Entire Talk]
Data can be a powerful ally in building diverse organizations.
Tony Mugavero,
Rad
Hype vs. Reality in VR [Entire Talk]
Connecting technological innovation to consumer demand requires flexibility, not certainty.
Tony Mugavero,
Rad
Hype vs. Reality in VR [Entire Talk]
Connecting technological innovation to consumer demand requires flexibility, not certainty.
Sarah Friar,
Nextdoor
Building Better Online Communities [Entire Talk]
How can you build respect into a social network?
Sarah Friar,
Nextdoor
Building Better Online Communities [Entire Talk]
How can you build respect into a social network?
